TD
Therapeutic Areas
Mycovia Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VIVJOA (oteseconazole) | Recurrent Vulvovaginal Candidiasis (RVVC) | Approved |
Leadership Team at Mycovia Pharmaceuticals
PJ
Patrick Jordan, MA, MBA
Chairman
SB
Stephen Brand, PhD
Chief Development Officer
RG
Rachel Gee
Chief Strategy Officer